Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Medigene AG's Enterprise Value is €25.20 Mil.
Medigene AG's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was €-16.04 Mil. Therefore, Medigene AG's EV-to-EBIT ratio for today is -1.57.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Medigene AG's Enterprise Value is €25.20 Mil.
Medigene AG's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was €-14.58 Mil. Therefore, Medigene AG's EV-to-EBITDA ratio for today is -1.73.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Medigene AG's Enterprise Value is €25.20 Mil.
Medigene AG's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was €6.03 Mil. Therefore, Medigene AG's EV-to-Revenue ratio for today is 4.18.
Medigene AG Enterprise Value Historical Data
The historical data trend for Medigene AG's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Medigene AG's Enterprise Value
For the Biotechnology subindustry, Medigene AG's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medigene AG's Enterprise Value Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Medigene AG's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Medigene AG's Enterprise Value falls into.
Medigene AG Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Medigene AG's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medigene AG (WBO:MDG1) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Medigene AG's current Enterprise Value is €25.20 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Medigene AG's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was €-16.04 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Medigene AG's current Enterprise Value is €25.20 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Medigene AG's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was €-14.58 Mil.
Medigene AG's current Enterprise Value is €25.20 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Medigene AG's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was €6.03 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medigene AG Enterprise Value Related Terms
Thank you for viewing the detailed overview of Medigene AG's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Medigene AG is an immuno-oncology biotechnology company. focused on developing differentiated T Cell Receptor engineered T cell (TCR-T) therapies for the treatment of multiple solid tumor indications with a high unmet medical need. The operating segments of the organization are Immunotherapies and Other products. Immunotherapies consist of T-cell receptor-based adoptive T-cell therapy and DC vaccines. The group operates in the United States, Germany, and Asia, of which the majority of the revenue is derived from operations in Germany.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
WBO:MDG1 has been successfully added to your 